HOME >> MEDICINE >> NEWS
Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

CD40L Moved Forward Based On Outcomes Of Multi-Dose Safety Trial

SEATTLE - Immunex Corporation (Nasdaq: IMNX) announced today that it has launched a Phase II trial of the investigational agent CD40 Ligand (CD40L) in the most common form of kidney cancer, renal cell carcinoma. The company is continuing the development of CD40L based on results of a multi-dose Phase I trial of the drug in advanced cancer patients.

The Phase I study, which evaluated escalating doses of CD40L in patients with recurrent solid tumors and lymphoma, has been completed and the objectives of the study were met. The results of this multi-dose study will be presented at a future medical meeting. Several pre-clinical studies on the anti-tumor effect of CD40L will be presented next week at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO). In these studies, conducted in both mice and fresh human tumor samples, CD40L inhibited tumor growth in multiple solid tumor types, such as breast, lung, ovarian and colon.

"Based on the results of these safety trials, Immunex is moving forward with a Phase II trial of CD40L in metastatic renal cell carcinoma," said Ann Hayes, M.D., senior vice president, medical development, Immunex. "Patients with this disease currently have limited treatment options. Treatment with CD40L represents a novel approach to treating cancer, by potentially having a direct effect on tumor cells and by stimulating the immune system to recognize and seek out cancer cells for destruction."

The study, being conducted in three cancer treatment centers across the United States, will evaluate the safety and efficacy of the drug in metastatic renal cell carcinoma.

Approximately 30,000 new cases of kidney cancer will be diagnosed this year in the United States and about 11,900 people will die from this disease. It is the 8th most common cancer in men and the 10th most common in women. Ren
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
14-May-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
4. Advances in plasma physics at Annual APS Meeting
5. Advances in plasma physics at Annual APS Meeting
6. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
7. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
8. Advances emerging in hepatitis management
9. Advances in prevention and treatment research hold promise for pipeline
10. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
11. Peanut Allergy: Major Advances in Treatment and Education

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/28/2020)... ... February 27, 2020 , ... Segal ... Carolina conducting Phase I-IV trials, is excited to announce the screening of its ... and efficacy of psilocybin for major depressive disorder (MDD). , Dr. Rishi Kakar ...
(Date:2/26/2020)... ... 26, 2020 , ... Join the live webinar ... PhD, Chief Technology Officer, Fluxion Biosciences as he provides an overview of ideal ... high-sensitivity circulating tumor cell (CTC) enrichment and recovery from blood samples, including samples ...
(Date:2/21/2020)... ... February 21, 2020 , ... Dr. Stong, a leading Atlanta facial plastic ... has been a long-time volunteer with Healing the Children (HTC) , traveling to ... is to provide cleft lip and palate procedures to underprivileged pediatric patients in the ...
(Date:2/21/2020)... ... 2020 , ... The American Society for Clinical Pathology (ASCP) ... MA, in October 2021. The prestigious, invitation-only event—organized by the Union for International ... health, city and industry leaders, senior executives and other influential players from ...
(Date:2/20/2020)... ... February 20, 2020 , ... ... a new release with next generation API integration functionality which enables agents ... VisitorsCoverage Inc. in 2017, TMQuotes was the first white label software-as-a-service (SaaS) ...
Breaking Medicine News(10 mins):
(Date:2/20/2020)... ... February 20, 2020 , ... Amada Senior Care ... in-home senior care from trained and knowledgeable Amada caregivers. From day one of ... meeting every client’s unique needs, preferences and desires, all with the goal of ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... ... on addressing unmet needs in the field of urology, today announced that Jayant ... Center of Excellence. The designation recognizes that Dr. Uberoi has achieved a high ...
(Date:2/20/2020)... (PRWEB) , ... February 20, ... ... national leader in government program modernization, has been selected to perform Independent ... and Human Services’ (EOHHS) Health Insurance Exchange and Integrated Eligibility System (HIX/IES) ...
Breaking Medicine Technology:
Cached News: